col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


39 Results       Page 1

 [1] 
Wiley: FEBS Journal
  original article Date Title Authors   All Authors
1 [GO] 2023―Oct―16 Differential specificity of SARS-CoV-2 main protease variants on peptide versus protein-based substrates Fernanda R. Rocho, Scott J. Snipas, Anwar Shamim, Wioletta Rut, Marcin Drag, Carlos A. Montanari, Guy S. Salvesen
2 [GO] 2023―Sep―02 Identification of a novel inhibitor of SARS-CoV-2 main protease: an in silico, biochemical, and cell-based approach Aditya Trivedi, Vandana Kardam, Krishna Kishore Inampudi, Sudhanshu Vrati, Dharmender Gupta, Aekagra Singh, et al. (+3)
3 [GO] 2023―Apr―26 Gene silencing of endothelial von Willebrand factor reduces the susceptibility of human endothelial cells to SARS-CoV -2 infection Giulia Furini, Alessandro De Carli, Rossella Fonnesu, Pietro Giorgio Spezia, Francesca Scebba, Mauro Pistello, et al. (+2)
4 [GO] 2023―Apr―04 Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses Ashlesha Deshpande, Nobert Schormann, Mike S. Piepenbrink, Luis Martinez Sobrido, James J. Kobie, Mark R. Walter
5 [GO] 2022―Oct―21 A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection Drugan K. Brady, Aashi R. Gurijala, Liyu Huang, Ali A. Hussain, Audrey L. Lingan, Olivia G. Pembridge, et al. (+4)
6 [GO] 2022―Aug―26 Core fucose-specific Pholiota squarrosa lectin ( PhoSL ) as a potent broad-spectrum inhibitor of SARS-CoV -2 infection Kazuhiko Yamasaki, Naruhiko Adachi, Mya Myat Ngwe Tun, Akihito Ikeda, Toshio Moriya, Masato Kawasaki, et al. (+6)
7 [GO] 2022―Aug―02 Effects of natural RNA modifications on the activity of SARS-CoV -2 RNA -dependent RNA polymerase Ivan Petushkov, Daria Esyunina, Andrey Kulbachinskiy
8 [GO] 2022―May―01 Emerging clinically tested detection methods for COVID-19 Milagros Castellanos, Álvaro Somoza
9 [GO] 2022―Feb―02 SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion Federica Quaglia, Edoardo Salladini, Marco Carraro, Giovanni Minervini, Silvio C.E. Tosatto, Philippe Le Mercier
10 [GO] 2021―Oct―20 Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies Zhenghu Jia, Chen Liu, Yuewen Chen, Heng Jiang, Zijing Wang, Jialu Yao, et al. (+4)
11 [GO] 2021―Oct―15 Cellular senescence as a source of SARS-CoV-2 quasispecies Ioannis Karakasiliotis, Nefeli Lagopati, Konstantinos Evangelou, Vassilis G. Gorgoulis
12 [GO] 2021―Sep―07 Protons to Patients: targeting endosomal Na + /H + exchangers against COVID-19 and other viral diseases Hari Prasad
13 [GO] 2021―Sep―07 Spotlight on COVID-19: eighteen months on Serena Zacchigna, Alessandro Marcello, Lawrence Banks
14 [GO] 2021―Jul―19 COVID-19 vaccines: what do we know so far? Paraminder Dhillon, Daniel Altmann, Victoria Male
15 [GO] 2021―Jul―06 Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2 Hongchun Lin, Xinxin Ma, Fang Xiao, Hua Su, Yaling Shi, Yuntao Liu, et al. (+4)
16 [GO] 2021―Jul―03 The role of T cell immunity in COVID-19 severity amongst people living with type II diabetes ZhenWei Marcus Tong, Emma Grant, Stephanie Gras, Melanie Wu, Corey Smith, Helen L. Barrett, et al. (+2)
17 [GO] 2021―Jun―29 Targeting Neuropilins as a viable SARS-CoV-2 treatment Sarvenaz Sarabipour, Feilim Mac Gabhann
18 [GO] 2021―May―17 Neurological consequences of neurovascular unit and brain vasculature damages: potential risks for pregnancy infections and COVID-19-babies Marco Rasile, Eliana Lauranzano, Filippo Mirabella, Michela Matteoli
19 [GO] 2021―May―10 Infection-induced inflammation from specific inborn errors of immunity to COVID-19 Cheng-Lung Ku, I-Ting Chen, Ming-Zong Lai
20 [GO] 2021―Apr―17 Host PDZ-containing proteins targeted by SARS-Cov-2 Célia Caillet-Saguy, Fabien Durbesson, Veronica V. Rezelj, Gergö Gogl, Quang Dinh Tran, Jean-Claude Twizere, et al. (+3)
21 [GO] 2021―Mar―23 Non-optimal codon usage preferences of coronaviruses determine their promiscuity for infecting multiple hosts Gon Carmi, Alessandro Gorohovski, Sumit Mukherjee, Milana Frenkel-Morgenstern
22 [GO] 2021―Mar―12 New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3’-5’ exoribonucleolytic activity on SARS-CoV-2 Margarida Saramago, Cátia Bárria, Vanessa G. Costa, Caio S. Souza, Sandra C. Viegas, Susana Domingues, et al. (+4)
23 [GO] 2021―Feb―23 The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection Eugene Merzon, Ilan Green, Shlomo Vinker, Avivit Golan-Cohen, Alessandro Gorohovski, Eva Avramovich, et al. (+2)
24 [GO] 2020―Dec―02 The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2 † Murat Seyran, Kazuo Takayama, Vladimir N. Uversky, Kenneth Lundstrom, Giorgio Palé, Samendra P. Sherchan, et al. (+18)
25 [GO] 2020―Oct―30 The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection Darren Z.L. Mok, Candice Yuen Yue Chan, Eng Eong Ooi, Chan Kuan Rong
26 [GO] 2020―Oct―24 Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients Hao-Long Zeng, Chen Di, Jingjun Yan, Qing Yang, Qiang-Qiang Han, Shu-Sheng Li, Liming Cheng
27 [GO] 2020―Sep―27 Announcing the winners of our COVID-19 Creative Communication Competition Paraminder Dhillon
28 [GO] 2020―Sep―27 Spotlight on COVID-19: from biology to therapy and prevention Serena Zacchigna, Alessandro Marcello, Lawrence Banks
29 [GO] 2020―Sep―27 Vitamin D to prevent COVID-19: recommendations for the design of clinical trials Carlos A. Camargo, Adrian R. Martineau
30 [GO] 2020―Aug―13 Nicotine and the nicotinic cholinergic system in COVID-19 Yousef Tizabi, Bruk Getachew, Robert L. Copeland, Michael Aschner
31 [GO] 2020―Aug―01 Tumor markers as an entry for SARS-CoV-2 infection? Pu Xia, Anna Dubrovska
32 [GO] 2020―Jul―23 Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study Eugene Merzon, Dmitry Tworowski, Alessandro Gorohovski, Shlomo Vinker, Avivit Golan Cohen, Ilan Green, Milana Frenkel Morgenstern
33 [GO] 2020―Jul―21 COVID-19, Cilia, and Smell Wei Li, Ming Li, Guangshuo Ou
34 [GO] 2020―Jul―12 Sympathetic activation: a potential link between comorbidities and COVID-19 Andrea Porzionato, Aron Emmi, Silvia Barbon, Rafael Boscolo-Berto, Carla Stecco, Elena Stocco, et al. (+2)
35 [GO] 2020―Jun―05 COVID-19 breakthroughs: separating fact from fiction Paraminder. Dhillon, Manuel. Breuer, Natasha. Hirst
36 [GO] 2020―May―23 A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2 Cassandra L. Atzrodt, Insha Maknojia, Robert D.P. McCarthy, Tiara M. Oldfield, Jonathan Po, Kenny T.L. Ta, et al. (+2)
37 [GO] 2020―May―19 Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing Oleg O. Glebov
38 [GO] 2020―May―17 Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank Alexander Wlodawer, Zbigniew Dauter, Ivan Shabalin, Miroslaw Gilski, Dariusz Brzezinski, Marcin Kowiel, et al. (+3)
39 [GO] 2020―Mar―19 Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? J.L. Olds, N. Kabbani
 [1] 

39 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.008 sec